Vaxxas
Hamilton
About Vaxxas
Vaxxas is a clinical-stage biotechnology company commercializing HD-MAP, a needle-free vaccine delivery system. Instead of conventional needles, HD-MAP uses tiny projections coated with dried vaccine, applied to the skin via a small patch and applicator. This innovation delivers the vaccine directly to immune cells just beneath the skin, triggering strong immune responses with potentially lower doses.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $162.2M
- Funding stage: Late Stage Venture
- Last round: Series D (Aug 2025)
- Website: vaxxas.com
- Phone: 61282057379
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/vaxxas-7891 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.